List of Excipients in Branded Drug ANASTROZOLE

Generic Drugs Containing ANASTROZOLE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	anastrozole	0093-7536	HYPROMELLOSE 2910
Teva Pharmaceuticals USA Inc	anastrozole	0093-7536	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA Inc	anastrozole	0093-7536	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	anastrozole	0093-7536	POLYETHYLENE GLYCOL 400

What are the Most Frequently-Used Excipients in ANASTROZOLE?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
9	CELLULOSE, MICROCRYSTALLINE
1	CI 77891
3	CROSCARMELLOSE SODIUM

Anastrozole Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Anastrozole is a mature, orally administered, nonsteroidal aromatase inhibitor with extensive generic competition in the United States and other major markets. Its core active-ingredient patent protection has expired, so commercial differentiation depends primarily on manufacturing cost, tablet robustness, supply reliability, regulatory execution, and patient-oriented formulation design.

The strongest excipient opportunities are incremental rather than radical: low-cost direct compression, reduced lactose or lactose-free tablets, improved disintegration, moisture control, swallowing aids, and differentiated packaging. A new formulation may require an ANDA only when it remains pharmaceutically equivalent to the reference product. Material changes in dosage form, release profile, route, or clinical performance can move the product toward a 505(b)(2) pathway.

What is anastrozole and how is it supplied?

Anastrozole is a selective, nonsteroidal aromatase inhibitor used primarily for hormone receptor-positive breast cancer in postmenopausal women. The standard marketed strength is a 1 mg immediate-release tablet taken once daily. The reference product is Arimidex, originally developed and marketed by AstraZeneca.

Attribute	Anastrozole
Active ingredient	Anastrozole
Pharmacologic class	Nonsteroidal aromatase inhibitor
Common strength	1 mg
Common dosage form	Film-coated immediate-release tablet
Reference product	Arimidex
Originator	AstraZeneca
Primary route	Oral
U.S. regulatory pathway	NDA 020541 for Arimidex; multiple ANDAs for generics
Main therapeutic use	Adjuvant and advanced breast cancer treatment
Biosimilar exposure	None; anastrozole is a small molecule
Current market structure	Generic and price-sensitive

Anastrozole has low-dose, high-potency characteristics. The 1 mg dose creates a favorable tablet-sizing profile, but it also makes blend uniformity and content uniformity important manufacturing controls. The product is generally suitable for conventional immediate-release tablet production.

What excipients are used in anastrozole tablets?

The reference formulation and generic formulations generally use conventional oral solid-dose excipients. Public labeling for anastrozole products identifies excipient classes that may include lactose monohydrate, povidone, sodium starch glycolate, magnesium stearate, hypromellose, polyethylene glycol or macrogol, and titanium dioxide, depending on the manufacturer and market. Exact excipient composition varies across approved products.[1-4]

Excipient class	Typical function	Commercial relevance
Lactose monohydrate	Diluent and compression aid	Low cost; supports tablet weight and manufacturability
Microcrystalline cellulose	Diluent and dry binder	Supports direct compression and lactose-reduced formulas
Povidone	Binder	Improves granule and tablet strength
Sodium starch glycolate	Superdisintegrant	Supports rapid tablet breakup
Crospovidone	Superdisintegrant	Alternative for fast disintegration and low-dose uniformity
Croscarmellose sodium	Superdisintegrant	Useful in direct-compression systems
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and may reduce manufacturing variability
Magnesium stearate	Lubricant	Required at controlled levels to avoid dissolution impact
Hypromellose	Film-coating polymer	Provides mechanical protection and appearance
Polyethylene glycol or macrogol	Plasticizer in film coat	Improves coating flexibility
Titanium dioxide or approved colorant	Opacifier or colorant	Supports product identification and appearance

Excipient selection should be assessed against the low dose of anastrozole. Excessive lubricant, poor segregation control, or inadequate blending can affect assay uniformity and dissolution. The formulation does not require a complex modified-release system for the conventional product.

Which excipient strategy is best for a generic anastrozole tablet?

The most defensible generic strategy is a conventional immediate-release film-coated tablet using a robust, low-cost excipient system that matches the reference product's critical quality attributes.

A practical baseline formulation may use:

• Lactose monohydrate or microcrystalline cellulose as the principal diluent.
• Povidone or another established binder where granulation is required.
• Sodium starch glycolate, crospovidone, or croscarmellose sodium as the disintegrant.
• Colloidal silicon dioxide to improve flow.
• Magnesium stearate at a controlled concentration and mixing time.
• Hypromellose-based film coating for protection and identification.

The preferred process depends on powder properties and equipment. Direct compression can minimize processing steps and cost, but it requires strong control of segregation, flow, and content uniformity. Wet granulation may provide better uniformity and compressibility but adds drying, energy, and scale-up requirements.

Direct compression

Direct compression offers the lowest process complexity and can support competitive generic pricing. It is attractive when the anastrozole premix has suitable flow and compressibility.

Key development controls include:

• Particle-size distribution of anastrozole and diluents.
• Blend segregation during transfer and hopper residence.
• Sampling strategy for low-dose content uniformity.
• Lubrication time and magnesium stearate distribution.
• Tablet hardness, friability, disintegration, and dissolution.
• Coating weight gain and moisture exposure.

Wet granulation

Wet granulation can improve homogeneity when the active ingredient has poor flow or poor distribution at low concentration. It may also reduce tablet defects. The disadvantages are higher manufacturing cost, longer cycle time, and greater process validation burden.

Roller compaction

Dry granulation may provide a middle path where direct compression is insufficient but wet granulation is undesirable. It can reduce water exposure and support continuous or semi-continuous processing. The main risks are ribbon-density variation, fines generation, and changes in dissolution after compaction.

What formulation opportunities exist for lactose-free or patient-friendly anastrozole?

Lactose-free anastrozole is the clearest excipient-led differentiation opportunity. Many patients do not require lactose avoidance, but lactose-free positioning can support hospital formularies, specialty pharmacy procurement, and patient preference programs.

A lactose-free formulation can replace lactose with:

• Microcrystalline cellulose.
• Mannitol.
• Dibasic calcium phosphate, subject to compatibility and tablet-density considerations.
• Pregelatinized starch.
• Coprocessed excipient systems.

Mannitol may improve mouthfeel and support orally disintegrating formats, but it can increase cost and may require tighter control of moisture and compression behavior. Microcrystalline cellulose is usually the more economical substitute for a standard swallowed tablet.

Other patient-oriented opportunities include:

Smaller tablets

A lower tablet mass can improve swallowing. This requires a high-functionality diluent and optimized compression profile. Smaller tablets may also reduce packaging volume and shipping cost.

Orally disintegrating tablets

An orally disintegrating tablet could target patients with dysphagia or difficulty taking conventional tablets. The opportunity is commercially narrower because anastrozole is taken chronically, the standard tablet is already small, and a new dosage form may require additional regulatory evidence.

An ODT strategy would require control of:

• Rapid disintegration.
• Mechanical strength.
• Taste and mouthfeel.
• Moisture sensitivity.
• Packaging protection.
• Dose uniformity.

Taste masking may require coating, complexation, ion-exchange technology, or a flavor system. These measures add cost and may reduce the commercial advantage unless the product has a defined patient-access or adherence objective.

Low-moisture formulations

Moisture-resistant excipient systems and high-barrier blister packaging may improve stability in hot and humid markets. The commercial value is strongest in regions with challenging distribution conditions, where stability failures and packaging losses create higher costs.

Tablet identification

Colorants, debossing, and distinctive film coatings can reduce dispensing errors. The value is operational rather than patent-based. A differentiated appearance must comply with local regulatory requirements and avoid confusing similarity to other oncology medicines.

What patents protect anastrozole formulations?

The principal composition-of-matter patent protection for anastrozole has expired. Anastrozole is therefore a mature generic market rather than an active new-molecule patent market.

IP category	Current commercial position
Active ingredient patent	Expired
Original Arimidex exclusivity	Expired
Standard immediate-release tablet	Broadly open to generic competition
Conventional excipients	Generally difficult to protect broadly
Novel formulation	Potentially protectable if new, non-obvious, and adequately supported
Manufacturing process	Potentially protectable if technically distinctive
Packaging or device	Potentially protectable, but usually narrow
Method of use	Historically relevant, but practical value depends on claim scope and expiry

A new excipient combination is unlikely to create meaningful patent value merely because the ingredients are combined in a conventional way. Stronger protection may be available where the formulation demonstrates an unexpected technical effect, such as materially improved stability, dissolution under challenging conditions, dose uniformity, or manufacturability.

Formulation patents should be drafted around measurable performance attributes rather than a generic list of excipients. Useful claim strategies may include:

• Defined excipient concentration ranges.
• A specified disintegration or dissolution profile.
• Moisture content or water-activity limits.
• A process linked to improved content uniformity.
• A stable polymorphic or amorphous form, where legally and technically supported.
• A specialized packaging and formulation combination.
• A patient-use format with a demonstrated clinical or adherence advantage.

When did anastrozole lose exclusivity?

Arimidex was approved by the FDA in December 1995. The five-year new chemical entity exclusivity period therefore expired in December 2000, subject to the statutory framework applicable at the time. The original anastrozole patent protection expired later, and generic entry followed after the relevant patent and regulatory barriers ended.[1,5]

The commercial result is a long-established generic market. Anastrozole does not present the exclusivity profile associated with recently approved oncology products, and new entrants compete primarily on supply, price, quality, and channel access.

What is the Orange Book status of anastrozole?

FDA Orange Book records identify the reference listed drug and relevant patent and exclusivity information for approved products. For a mature generic such as anastrozole, the commercial focus is not on blocking originator patents but on determining which product can serve as the reference for an ANDA and whether any listed patents remain relevant to a proposed product.[5]

An ANDA applicant must address listed patents through the applicable certification pathway. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed. For anastrozole, the practical importance of Paragraph IV litigation is historical rather than a central current-market barrier.

Which companies challenge anastrozole patents?

Generic manufacturers and distributors have entered the anastrozole market through ANDAs and equivalent pathways outside the United States. Historical generic competition included major multinational generic companies and regional manufacturers. The current opportunity is not defined by a single challenger but by a broad supplier base.

The main competitive variables are:

• Approved manufacturing sites.
• API sourcing and dual-source capability.
• FDA inspection history.
• Ability to maintain uninterrupted supply.
• Wholesale acquisition price and contract pricing.
• Hospital and group purchasing organization access.
• Product availability in 30-, 90-, and 100-count configurations.
• International registration and local tender performance.

A new entrant must compete against established manufacturers with lower per-unit costs and validated supply chains. A formulation improvement alone may not overcome a major manufacturing or procurement disadvantage.

What FDA regulatory pathway applies to a new anastrozole formulation?

A conventional immediate-release anastrozole tablet is generally suited to the ANDA pathway if it demonstrates pharmaceutical equivalence and bioequivalence to the reference listed drug.[6]

A 505(b)(2) application may be more appropriate when the product differs materially from the reference product, such as:

• Orally disintegrating tablet.
• Alternative route of administration.
• New dosage form.
• Modified-release profile.
• New strength or dosing configuration.
• Formulation with clinical or pharmacokinetic differentiation.

The regulatory value of an excipient innovation depends on whether it changes a clinically relevant product attribute. A new excipient system that produces the same immediate-release performance may fit within an ANDA. A formulation that changes exposure, administration, or patient use may require a broader evidence package.

Excipients must comply with applicable FDA requirements, including appropriate compendial status, prior use, or safety justification. Novel excipients can create a regulatory barrier that is disproportionate to the commercial value of a low-price generic oncology product.[7]

How strong is the anastrozole patent estate?

The patent estate is weak as a barrier to standard generic entry and potentially moderate for a genuinely differentiated formulation.

Asset type	Patent strength for new entrants
Standard 1 mg tablet	Low barrier
Conventional lactose-based formulation	Low barrier
Lactose-free formulation	Potentially protectable, but usually narrow
ODT formulation	Moderate if supported by technical data
Novel manufacturing process	Moderate if non-obvious and difficult to design around
Packaging system	Usually narrow
New therapeutic indication	Dependent on claim scope and remaining term
API process or solid form	Moderate if technically distinct and commercially necessary

Freedom-to-operate analysis should focus on active patents covering specific solid forms, processes, formulations, and use claims. The expired core compound patent does not eliminate the need to review later-filed patents.

What commercial opportunities remain for anastrozole excipients?

The strongest opportunities are concentrated in operational and channel-specific niches.

Cost reduction

A lower-cost excipient system can improve gross margin if it reduces granulation, coating, rejection, or testing costs. The largest value often comes from process simplification rather than the lowest individual excipient price.

Supply-chain resilience

Dual-sourceable excipients and regional sourcing can reduce production interruptions. This is important for oncology products, where stockouts can trigger hospital substitution and loss of formulary position.

Emerging-market stability

Moisture-protective formulations, alu-alu blister packs, and robust coatings can support registrations in tropical and subtropical markets. The value proposition is strongest where distribution infrastructure is variable.

Lactose-free positioning

A lactose-free tablet can create a procurement distinction, particularly for hospitals and specialty pharmacies with excipient-screening policies. It is unlikely to support a large price premium without a clear access or patient-adherence benefit.

Pediatric or pre-adolescent oncology use

Anastrozole is not primarily a pediatric product, but specialized low-dose or liquid concepts could address defined clinical settings. Such products would require careful dosing, stability, palatability, and regulatory analysis. The market is likely narrower than the conventional adult tablet market.

Combination packaging

Co-packaged anastrozole with supportive-care medicines may improve adherence or dispensing convenience. The commercial and regulatory structure would depend on whether the products are merely packaged together or combined into a new drug product.

Contract development and manufacturing

CDMOs can offer value through platform formulations, low-dose blend-uniformity expertise, analytical method transfer, and multi-market regulatory packages. Anastrozole is suitable for a standardized development platform because the dosage form is conventional and the API dose is low.

How does anastrozole compare with letrozole and exemestane?

Anastrozole competes with other aromatase inhibitors, particularly letrozole and exemestane. All three are established oral products, but their excipient and formulation opportunities differ.

Product	Chemical class	Typical form	Formulation opportunity
Anastrozole	Nonsteroidal aromatase inhibitor	1 mg immediate-release tablet	Lactose-free, small tablet, ODT, stability-focused packaging
Letrozole	Nonsteroidal aromatase inhibitor	2.5 mg immediate-release tablet	Similar generic cost and excipient opportunities
Exemestane	Steroidal aromatase inhibitor	25 mg tablet	Greater tablet-mass and dissolution considerations

Anastrozole's 1 mg dose supports a small tablet and makes low-dose content uniformity a central technical issue. Exemestane's higher dose may create more substantial tablet-size and dissolution design constraints. Commercial buyers are likely to evaluate these products as therapeutic alternatives, so price, availability, and formulary status can outweigh modest excipient differentiation.

What generic launch risks exist for anastrozole?

A new generic anastrozole launch faces limited patent risk but meaningful commercial and execution risk.

Primary risks include:

1. Excess supplier concentration and aggressive price erosion.
2. API sourcing problems or impurity-control failures.
3. Blend-uniformity failures caused by low-dose active loading.
4. Dissolution changes from over-lubrication or excessive compression.
5. Scale-up differences between laboratory and commercial equipment.
6. FDA inspection findings at the drug-product or API site.
7. Inability to secure wholesaler, hospital, or group purchasing contracts.
8. Insufficient differentiation to justify launch and inventory costs.
9. Packaging failures in high-temperature or high-humidity markets.
10. Later-filed formulation or process patents affecting a differentiated product.

The most attractive launch model is usually a low-cost, reliable, multi-market tablet rather than a high-cost novel dosage form. A specialized formulation should be supported by a clear reimbursement, adherence, supply, or geographic strategy.

What revenue exposure exists for anastrozole manufacturers?

Anastrozole revenue is exposed to generic price erosion and therapeutic substitution. The market is unlikely to support originator-style margins for a conventional tablet. Revenue depends on volume, manufacturing efficiency, channel reach, and the number of approved competitors.

A manufacturer can improve revenue quality through:

• Multi-country registrations.
• Hospital and tender contracts.
• Reliable 90-day retail supply.
• Private-label and white-label manufacturing.
• Dual-source API qualification.
• Lactose-free or excipient-controlled variants.
• Contract supply to oncology-focused distributors.
• Portfolio bundling with letrozole and exemestane.

A formulation patent may increase asset value only if it protects a product with a defined commercial advantage. Patent ownership without channel access or manufacturing scale is unlikely to create durable returns in this market.

Key Takeaways

• Anastrozole is a mature generic oncology product with expired core exclusivity.
• Conventional immediate-release tablets should generally be developed through an ANDA when pharmaceutical equivalence and bioequivalence can be established.
• The most practical excipient strategies are direct compression, lactose reduction or elimination, optimized disintegration, low-moisture processing, and robust film coating.
• Low-dose content uniformity, segregation, lubrication, and dissolution are the main formulation risks.
• ODT, liquid, and other patient-oriented formats may support 505(b)(2) opportunities but require stronger commercial justification.
• Conventional excipient combinations have limited patent strength unless supported by unexpected technical performance.
• The best commercial opportunities are cost reduction, supply resilience, emerging-market stability, lactose-free positioning, and CDMO services.
• Biosimilar risk is irrelevant because anastrozole is a small-molecule drug.
• Generic launch risk is primarily commercial and operational, not based on the expired originator patent estate.

FAQs

Can anastrozole be formulated without lactose?

Yes. Microcrystalline cellulose, mannitol, pregelatinized starch, and other diluents can replace lactose. The formulation must maintain content uniformity, tablet strength, disintegration, dissolution, and stability.

Is anastrozole suitable for an orally disintegrating tablet?

Yes, technically. The commercial case is narrower because the conventional tablet is already small and easy to manufacture. An ODT would need meaningful patient or adherence value to justify added development and packaging costs.

Are anastrozole excipients patentable?

They can be patentable when a formulation contains a novel, non-obvious combination or produces an unexpected technical effect. A routine substitution of lactose with microcrystalline cellulose is unlikely to provide broad, durable patent protection.

Does anastrozole have biosimilar competition?

No. Biosimilar rules apply to biologic products. Anastrozole is a small molecule and is supplied through generic-drug pathways such as ANDAs.

What is the most attractive commercial formulation for anastrozole?

A low-cost, lactose-free or excipient-controlled immediate-release film-coated tablet with strong blend uniformity, stable packaging, and reliable multi-market supply is generally more commercially attractive than a complex novel dosage form.

References

1. U.S. Food and Drug Administration. (1995). Arimidex (anastrozole) prescribing information, NDA 020541. FDA Drugs@FDA.
2. DailyMed. (n.d.). Anastrozole tablet prescribing information. National Library of Medicine.
3. European Medicines Agency. (n.d.). Arimidex: Product information. EMA.
4. Electronic Medicines Compendium. (n.d.). Anastrozole film-coated tablet product information.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
6. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. FDA.
7. U.S. Food and Drug Administration. (2019). Guidance for industry: Nonclinical studies for the safety evaluation of pharmaceutical excipients. FDA.